MPM BioImpact Portfolio holdings
MPM BioImpact runs biotech venture, hybrid and hedge funds, and its impact funds put private and public money into companies aiming to change outcomes for patients with disease. Its hedge funds concentrate on small and mid-sized healthcare companies, while the firm as a whole combines MPM Capital's biotech venture capital record of more than 30 years with BioImpact's public investing. The firm was called MPM Oncology Impact Management until 2021 and BioImpact Capital until 2023. Ansbert Gadicke, its founder and managing partner, is also its controlling owner. Among its portfolio stories, it built the radiopharmaceutical company Aktis Oncology for solid tumors and was an early backer of argenx, an immunology company.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intellia Therapeutics
NTLA
|
+$24.6M |
| 2 |
BioCryst Pharmaceuticals
BCRX
|
+$11.1M |
| 3 |
ESSA Pharma
EPIX
|
+$10.9M |
| 4 |
EPZM
Epizyme
EPZM
|
+$10M |
| 5 |
Verastem
VSTM
|
+$8.65M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cullinan Therapeutics
CGEM
|
+$7.1M |
| 2 |
iTeos Therapeutics
ITOS
|
+$6.05M |
| 3 |
Repare Therapeutics
RPTX
|
+$1.17M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.65% |
| 2 | Miscellaneous | 5.35% |
Similar funds
MPM BioImpact's Q3 2021 Portfolio in Review
As of Q3 2021, MPM BioImpact held 33 positions worth $645M, up 5.9% from $609M the previous quarter. Its ten largest holdings account for 72% of the portfolio.
MPM BioImpact deployed $150M of net new capital in Q3 2021, opening 19 new positions and adding to 7 existing holdings. Its largest new stake was Intellia Therapeutics: 162,620 shares worth $21.8M.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 95% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Cullinan Therapeutics, an estimated $7.1M trimmed.
- MPM BioImpact's largest Q3 2021 buy was Intellia Therapeutics: 162,620 shares worth $21.8M.
- MPM BioImpact added most to Epizyme in Q3 2021, an estimated $10M increase.
- MPM BioImpact's biggest Q3 2021 reduction was Cullinan Therapeutics, cutting an estimated $7.1M.
- MPM BioImpact's ten largest holdings make up 72% of its $645M portfolio in Q3 2021.
- MPM BioImpact opened 19 new positions and closed 0 in Q3 2021.
- MPM BioImpact's portfolio value rose 5.9% quarter-over-quarter to $645M.
Based on MPM BioImpact's 13F filing for Q3 2021, filed 15 Nov 2021.